Live Breaking News & Updates on Frontier biotechnologies inc

Stay informed with the latest breaking news from Frontier biotechnologies inc on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Frontier biotechnologies inc and stay connected to the pulse of your community

Chronic Lower Back Pain Market is expected to rise at a CAGR of 3.85% during the study period (2019–2032), estimates DelveInsight |

Chronic Lower Back Pain Market is expected to rise at a CAGR of 3.85% during the study period (2019–2032), estimates DelveInsight |
medgadget.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medgadget.com Daily Mail and Mail on Sunday newspapers.

United-states , United-kingdom , Japan , Vertanical-gmb , Eli-lilly , Braeburn-inc , Chronic-lower-back-pain-companies , Discgenics-inc , Pfizer , Healthcare-market-research , Frontier-biotechnologies-inc , Persica-pharmaceuticals

Global COVID-19 Competitive Landscape Report 2023: Comprehensive Insights on 400+ Companies and 500+

DUBLIN--(BUSINESS WIRE)--The "COVID-19 - Competitive Landscape, 2023" report has been added to ResearchAndMarkets.com's offering.This "COVID-19 Competitive landscape 2023" report provides comprehensive insights about 400+ companies and 500+ drugs in COVID-19 Competitive landscape. It covers the therapeutics assessme...

United-states , Shenzhen , Guangdong , China , Mali , India , Vietnam , Republic-of , France , America , Nanogen-nanocovax , Akston-biosciences

Chronic Lower Back Pain Global Market Report 2023

Major players in the chronic lower back pain market are Pfizer Inc., Johnson & Johnson Private Limited, Sanofi S.A., Endo Pharmaceuticals Plc., Merck...

United-states , United-kingdom , Brazil , Germany , Indonesia , California , Ukraine , New-york , Eterna , Niedersachsen , San-diego , India

COVID-19 oral meds market good pill to swallow

Eyeing the huge market potential, pharmaceutical enterprises are ramping up efforts to grab a share of the COVID-19 preventative oral medicine market in China and the rest of the world.

China , Henan , Philippines , Shanghai , Wuhan , Hubei , Chinese , Deng-zhidong , Junshi-biosciences , Simcere-pharmaceutical-group-ltd , Chinese-academy-of-sciences , Pfizer

TOT BIOPHARM Reached New Milestones in Interim -2-

DJ TOT BIOPHARM Reached New Milestones in Interim Results, with Sales Volume of over RMB 100 million, a Significantly Improved Capital Structure EQS Newswire / 15/08/2022 / 10:26 UTC+8 TOT BIOPHARM

China , Hong-kong , Jixin , Hainan , Tibet-autonomous-region , Xizang , Hebei , Jilin , Suzhou , Jiangsu , Macao , Macau-general-

TOT BIOPHARM Reached New Milestones in Interim Results, with Sales Volume of over RMB 100 million, a Significantly Improved Capital Structure

DJ TOT BIOPHARM Reached New Milestones in Interim Results, with Sales Volume of over RMB 100 million, a Significantly Improved Capital Structure EQS Newswire / 15/08/2022 / 10:26 UTC+8 TOT BIOPHARM

China , Hong-kong , Jixin , Hainan , Tibet-autonomous-region , Xizang , Hebei , Jilin , Suzhou , Jiangsu , Macao , Macau-general-

Frontier Biotechnologies announces positive phase 1 results of its first coronavirus main protease (Mpro) small molecule inhibitor

Atlanta (Georgia) [US], August 10 (ANI/PRNewswire): Frontier Biotechnologies, a biopharmaceutical company focused on the discovery, development and dissemination of innovative medicines that improve patient health, announced positive results from the Phase 1 clinical trial of its drug candidate, FB2001 - a small molecule inhibitor of coronavirus main protease (Mpro) - in healthy adult volunteers. The data, presented today at the poster session of the 11th International Conference on Emerging Infectious Diseases (ICEID), showed FB2001 to be safe and well tolerated among trial participants. Adverse events reported during the trial were mostly mild-to-moderate in severity, with no significant differences observed between participants in the Chinese and American study centers. "We are pleased by the positive results from FB2001's phase 1 trial. It is a significant milestone for us and the healthcare community", said Dr CJ Wang, Chief Executive Officer of Frontier Biotechnologies. "This promising result will spur us on to strive for success in later-stage trials. We believe that the work done at Frontier Biotech can elevate our efforts in the fight against COVID-19 in China and abroad." A total of 120 participants (80 Whites in the US and 40 Chinese in China) received intravenous infusions of FB2001 at either single doses from 5 mg to 400 mg, or multiple doses of 30 mg to 400 mg daily for 5 days. The key findings from the study are as follows: - FB2001 was safe and well tolerated up to 400 mg per day - Without using a pharmacokinetic enhancer, FB2001 exhibited plasma and lung drug concentration above the in vitro antiviral EC50 value. - No significant difference was observed between Chinese and American populations. The results from the Phase 1 trial build on preclinical in vivo data of FB2001, where the drug was observed to reduce viral loads in both the lung and brain tissues of mice. Pharmacokinetic data obtained from preclinical studies showed significantly higher concentration of FB2001 in the lung compared to plasma. "FB2001 has demonstrated in vivo antiviral activity in the lung and brain tissue of SARS-CoV-2 mouse model without the need for pharmacokinetic boosting. Therefore, it holds great promise as a treatment for acute COVID-19 as well as long-COVID, both of which will be evaluated in further follow-up studies", said Dr Jay Lalezari, MD, Medical Director of Quest Clinical Research in San Francisco. The current intravenous formulation of FB2001 is ideal for hospitalized patients with its rapid onset of action and is suited for patients with dysphagia or other problems with swallowing. Working with clinical research organizations, regional regulatory agencies, and local clinical centers, Frontier Biotechnologies has started a pivotal Phase 2/3 study (BRIGHT trial) to enroll about 1,200 hospitalized patients in hundreds of clinical centers worldwide. "The phase 1 data were really promising", said Dr Michael Hu, Chief Medical Officer of Frontier Biotechnologies, "and we are confident to carry out the pivotal trial to explore the utility of the drug in reducing the time to recovery in hospitalized patients due to COVID-19." Frontier Biotechnologies is also developing a pulmonary formulation of FB2001 that could be used in outpatient setting for the treatment of mild Covid-19, as well as for post-exposure prophylaxis. When inhaled directly into the respiratory tract and lungs, the tissue concentration of FB2001 is much higher than that in plasma; hence, the onset of action and viral clearance could potentially be faster than that of oral therapy. Founded in 2013, Frontier Biotechnologies Inc. ("Frontier Biotech") is a commercial-stage biopharmaceutical company headquartered in China with global vision and world-class competitiveness. Frontier Biotech is committed to discovering, development, manufacturing, and commercialization of innovative medicines that improve patient health. CONTACT: Weber Shandwick, Joey Toh, E:j.toh@webershandwick.com, M:+65-9758-5817, Timothy Cheok, E:tcheok@webershandwick.com; M:+65 9054 0476, Ben Hickey, E:bhickey@webershandwick.com, M:+65-9070-3305 This story is provided by PRNewswire. ANI will not be responsible in any way for the content of this article. (ANI/PRNewswire)

United-states , San-francisco , California , China , Georgia , Chinese , American , Ben-hickey , Jay-lalezari , Weber-shandwick , Joey-toh , Frontier-biotechnologies-inc

AFFiRiS and Frontier Biotechnologies announce license agreement for AFFITOPE®AT04, an active immunotherapy targeting PCSK9 to treat hypercholesterolemia, in Greater China

AFFiRiS and Frontier Biotechnologies announce license agreement for AFFITOPE®AT04, an active immunotherapy targeting PCSK9 to treat hypercholesterolemia, in Greater China

GlobeNewswire

December 22, 2021

Frontier Biotechnologies obtains exclusive rights to develop and commercialize AFFITOPE® AT04 in Greater China Collaboration accelerates the global development of AFFiRiS potential first-in-class active immunotherapy with plans to...

China , Taiwan , Austria , United-states , Vienna , Wien , Hong-kong , Macau , Immunotherapies-saits , Richard-zhao , Donald-xu , Noel-barrett

Frontier Biotechnologies' First Long-acting Injectable (Aikening(R)), in a Two Drug Regimen for HIV, Proves Safe and Efficacious for Patients

Frontier Biotechnologies' First Long-acting Injectable (Aikening(R)), in a Two Drug Regimen for HIV, Proves Safe and Efficacious for Patients
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

China , Berlin , Germany , Dong-xie , Zhejiang , Chinese , Datuk-adeeba-kamarulzaman , Wu-hao , Frontier-biotechnologies-inc , Infection-division-in-you-an-hospital , Drug-administration , Capital-medical-university

April 2021 CDMO Opportunities And Threats Report

Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities...

Japan , Philadelphia , Pennsylvania , United-states , Japanese , Mibe-gmbh-arzneimittel , Immunbiologische-forschung-gmb , Biologika-gmb , Vibalogics-gmb , Boehringer-ingelheim , Laboratorio-reig-jofre , Eli-lilly